Evaluating Home Testing Devices for the Management of Glaucoma
Glaucoma, Open-Angle
About this trial
This is an interventional diagnostic trial for Glaucoma, Open-Angle focused on measuring Open Angle Glaucoma, Perimetery, Tonometry, Eye Pressure, Visual Field, Home Test
Eligibility Criteria
Inclusion Criteria:
- Age 20-80 years
- Mild and Moderate Open Angle Glaucoma (OAG)
- Refraction under 12.00 diopter of spherical refractive error and astigmatism of less than 2.5 diopter.
Exclusion Criteria:
- Spherical refraction outside > ± 12.00 D and cylinder correction > +2.5 D.
- Visual acuity worse than 20/50 either eye
- Cataract surgery with or without Minimally Invasive Glaucoma Surgery (MIGS) less than 90 days prior to enrollment
- Filtering surgeries less than 6 months prior to enrollment
Intraocular surgery other than:
- Non-complicated MIGS more than 90 days prior to enrollment;
- Cataract or refractive surgery performed more than 90 days before enrollment and without posterior capsule opacification
- Other glaucoma surgery more than 6 months prior to enrollment.
- History of systemic or ocular condition (other than glaucoma or mild to moderate cataract) known to affect visual function.
- History of medication known to affect visual function or influence patient reaction time
- Inability to use device after remote training session
- Subjects unwilling and/or unable to participate
Sites / Locations
- Wills Eye HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Moderate Glaucoma
Subjects between ages 20-80 years with a diagnosis of mild and moderate Open Angle Glaucoma in at least one eye with 20/50 vision or better will be included in this study. All subjects will have the Olleyes Perimeter measure their own visual acuity and field once a week during a 2 year period and iCare home to measure their eye pressure 3 times a day for 7 days every 3 months during a 2 year period. All patient will have their routine glaucoma assessment with the standard 24-2 Automatic Perimetry Humphrey Field Analyzer at baseline and every 6 months during a 2 year period; and Spectralis Optical Coherence Tomography thickness of peripapillary RNFL and macular ganglion cell at baseline and yearly during a 2 year period.